Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: A meta-analysis

European Heart Journal

Volumn 28, Issue 4, 2007, Pages 457-462

  Nasr, Imad Abi ^a   Bouzamondo, Anissa ^a   Hulot, Jean Sébastien ^a   Dubourg, Olivier ^a   Le Heuzey, Jean Yves ^b   Lechat, Philippe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Atrial fibrillation; Beta blocker; Heart failure; Meta analysis; Primary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NEBIVOLOL; PLACEBO;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; RISK REDUCTION; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; CHRONIC DISEASE; DOUBLE-BLIND METHOD; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 34547646848     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl484     Document Type: Article

References (48)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
2. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.
3. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925.
4. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T, Guize L. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147:121-126.
5. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292.
6. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
7. Blackshear JL, Safford RE. AFFIRM RACE trials: implications for the management of atrial fibrillation. Card Electrophysiol Rev 2003;7:366-369.
8. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme and angiotensin receptor blockers. J Am Coll Cardiol 2005;45:1832-1839.
9. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
10. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
11. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
12. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, Remme W, Sharpe DN, Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Trial. J Am Coll Cardiol 2005;45:525-530.
13. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212- 218.
14. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
15. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure.MOCHA Investigators. Circulation 1996;94:2807-2816.
16. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-2799.
17. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-2806.
18. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The US Carvedilol Heart Failure Study Group. J Card Fail 1997;3:173-179.
19. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
20. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
21. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med 2001;344:1651-1658.
22. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
23. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
24. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950.
25. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischaemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-384.
26. Waagstein F, Stromblad O, Andersson B, Bohm M, Darius M, Delius W, Goss F, Osterziel KJ, Sigmund M, Trenkwalder SP, Wahlqvist I. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischaemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail 2003;5:679- 691.
27. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
28. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P. Dose-response of chronic b-blocker treatment in heart failure from either idiopathic dilated or ischaemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-1642.
29. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603- 607.
30. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R. Beta-blockade with bucindolol in heart failure caused by ischaemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
31. The BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (BEST). N Engl J Med 2001;344:1659-1667.
32. Lechat PB, Komajda M. Pilot study of cardiovascular effect of nebivolol in congestive heart failure. Drug Invest 1991;3:69-81.
33. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
34. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. Eur Heart J 2005;26:215-225.
35. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
36. Kalifa J, Jalife J, Zaitsev AV, Bagwe S, Warren M, Moreno J, Berenfeld O, Nattel S. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-671.
37. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ (eds). Atrial Fibrillation: Mechanisms and Management. New York: Raven Press; 1992. p109-125.
38. Campbell DL, Rasmusson RL, Comer MB, Strauss HC. The cardiac calcium-independent outward potassium current: kinetics, molecular properties, and role in ventricular repolarization. In: Zipes DP, Jalife J (eds). Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: Saunders; 1995. p83-96.
39. Daoud EG, Bogun F, Harvey M, Man C, Strickberger SA, Morady F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-1606.
40. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K1 current similar to Kv1. 5 cloned channel currents. Circ Res 1993;73:1061-1076.
41. Li G-R, Feng J, Wang Z, Fermini B, Nattel S. Adrenergic modulation of ultrarapid delayed rectifier K1 current in human atrial myocytes. Circ Res 1996;78:903-915.
42. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003;107:1930-1936.
43. Tjandrawidjaja MC, Fu Y, Kim DH, Burton JR, Lindholm L, Armstrong PW. CAPTORS II Investigators. Compromised atrial coronary anatomy is associated with atrial arrhythmias and atriventricular block complicating acute myocardial infarction. J Electrocardiol 2005;38:271-278.
44. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. AHA Medical/Scientific Statement Special Report: management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996;93:1262-1277.
45. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Matthias P, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized double blind placebo controlled study. J Am Coll Cardiol 2000;36:139-146.
46. The AF-CHF investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002;144:197-607.
47. Packer M, Fowler MB, DeMets DL. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-2199.
48. Prakash C, Giles TD, Wikstrand J, on behalf of the MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159-167.